CLINICAL TRIALS PROFILE FOR YONDELIS
✉ Email this page to a colleague
All Clinical Trials for Yondelis
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00060944 ↗ | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | Completed | PharmaMar | Phase 2 | 2003-05-01 | The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma. |
| NCT00060944 ↗ | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2003-05-01 | The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma. |
| NCT00070109 ↗ | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | Completed | National Cancer Institute (NCI) | Phase 2 | 2008-01-01 | This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00070109 ↗ | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | Completed | Children's Oncology Group | Phase 2 | 2008-01-01 | This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00072670 ↗ | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | Completed | PharmaMar | Phase 2 | 2004-01-01 | The purpose of this study is to evaluate safety and efficacy of trabectedin (ET-743) in adult male participants with advanced metastatic (spread of cancer cells from one part of the body to another) prostate cancer. |
| NCT00072670 ↗ | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2004-01-01 | The purpose of this study is to evaluate safety and efficacy of trabectedin (ET-743) in adult male participants with advanced metastatic (spread of cancer cells from one part of the body to another) prostate cancer. |
| NCT00102609 ↗ | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | Completed | PharmaMar | Phase 1 | 2005-04-01 | The purpose of the study is to determine the dose of the combination of trabectedin (Yondelis) and Doxorubicin for which neutropenia (low white blood cell counts) could be managed with filgrastim (a Granulocyte-Colony Stimulation Factor that is used to help control neutropenia) in patients with a type of cancer called soft tissue sarcoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Yondelis
Condition Name
Clinical Trial Locations for Yondelis
Trials by Country
Clinical Trial Progress for Yondelis
Clinical Trial Phase
Clinical Trial Sponsors for Yondelis
Sponsor Name
